Novocure Ltd (NVCR)

[jondoeuk]

Simply put, no.

[rick172]

Wow is NWBO really a threat?

[whosleftholdindabag]

Hello everyone, I got back into $NVCR this morning, 5K starter shares, will add on weakness! GLTA

[KIPK]

Plug away - Fake device for cure?? Na.. End is near..

[jondoeuk]

Novocure aims to plough a new field https://www.evaluate.com/vantage/articles/interviews/novocure-aims-plough-new-field

[KIPK]

Why HyGro is so worried??. He spends lots of time on NWBO MB. hummm

[KIPK]

Better head in the sand than in a microwave hat!!

[jondoeuk]

Ignore it.

[KIPK]

Today News: After a review of Novocure’s future needs, Ely Benaim, M.D., Chief Medical Officer, will step down from his role and leave the company.

Very Telling Where this is headed....

[rick172]

Why is this going down?

[CrashOverride]

Crackheads love Optune.

[KIPK]

Very Telling. The 6 officers combined sold over 260,000 shares all about $100/Share..
That's over $26M worth of shares they dumped!!

[abc1212]

Did anyone else read this telling post

Did you see CEO, chief science officer, and chief development officer from NVCR dump their shares at peak four days before the 4th quarter report out which listed only 10 new patients recruited last quarter? They know better about the NVCR's destiny. [/quote

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170921932




.

[exwannabe]

It's strange there's no activity on this board. Something doesn't seem right.

For whatever reason this message board was dead several years ago, The only posts were basically from the NWBO board posters who consider NVCR the evil opponent.

For NVCR, the GBM indication was never going to be worth the market cap. It is a modest market that will pay bills but never be huge,

The NSCLC indication is a game changer for 2 reasons. First, the market itself is much larger. But also, success outside of the brain (which was TTF's sweet spot) is huge as it portends well for other cancers.

Nothing very sexy about what might well be no more than a better chemo (it kills cells that divide but has little AEs). But sometimes just being better is a huge win.

We shall see.

[rick172]

It's strange there's no activity on this board. Something doesn't seem right.

[Penny chatter]

How's it going?

[KIPK]

The Big Short - SCAM alert- The heat cap is at best as good as CHEMO!! IMO

[Long and gone]

Anyone else think this thing is a high level scam. I don’t think they have one 5 yr survivor

[DrHigh]

Did the CEO dump virtually his entire position? WTF is that about

[KIPK]

You got that Absolutely right norisknorewards..
NVCR ends is closer than what that dude wishes not to be...
The device is no better than CHEMO!!

[Penny chatter]

Easiest short he said

[Penny chatter]

We shall see

[KIPK]

FDA Cleared CHEMO as well just incase... And that has miserably failed///

There is absolutely NO CURE in NoVoCure!!

Best Short EVER IMO

This below statement from their PR confirms that fact!!

".....which has the Potential to meaningfully extend patient survival beyond what was previously possible.,& that says it all. |the Potential .. to extend ..Survival" ... Its all that she wrote~~~~

[Penny chatter]

Could be this am conference today?


Novocure plans to release the full results of the LUNAR study at a future medical conference. Novocure expects to file a Premarket Approval application with the U.S. Food and Drug Administration (FDA) in the second half of 2023. Novocure also expects to file for a CE Mark in the European Union concurrently with the FDA submission.

[Penny chatter]

“We are pleased with the positive readout of the LUNAR study. Prior to LUNAR, the last phase 3 trial to lead to significant improvement in overall survival in late-stage, platinum-resistant non-small cell lung cancer was six years ago, underlining the difficulty in treating this disease,” said William Doyle, Novocure’s Executive Chairman. “We are also pleased by the profound performance of the TTFields together with immunotherapy, which has the potential to meaningfully extend patient survival beyond what was previously possible. I would like to thank our patients and investigators for their courage and dedication in completing LUNAR. And, I would like to thank Novocure’s employees for their unrelenting commitment to patients and their perseverance in propelling Novocure to this major milestone.”

“We are excited about the potential of TTFields to address the unmet medical needs of lung cancer patients around the world. In China, lung cancer is the most common cancer type with approximately 700,000 new NSCLC cases diagnosed each year,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “We are pleased to contribute and be a part of the LUNAR study and this partnership is yet another great example of how collaboration benefits everyone.”

Novocure plans to release the full results of the LUNAR study at a future medical conference. Novocure expects to file a Premarket Approval application with the U.S. Food and Drug Administration (FDA) in the second half of 2023. Novocure also expects to file for a CE Mark in the European Union concurrently with the FDA submission.

[Penny chatter]

I penny pumper writing a narrative that's about to get burnt. Fda clearance is huge!!

[KIPK]

NVCR microwave device hype will not last and rapidly fading!!

Those who understand how it works know that its application is at best comparable to chemo in terms of effectiveness & the real life experiences of the prescribing doctors & their cancer patients has been increasingly confirming that!!

Why do you think with a bloated $10B market cap, its earnings are non-existence and dropping??

Comparatively speaking, Chemo kills the cancer as well as the normal cells..

And the helmet, based on it claim mode of action of interfering with replication of fast dividing cells, such as cancer cells, inhibit the division of those cells at the site where the microwaves are targeting. Obviously elsewhere in the body, the cancer cells lives happily and keep invading..

Now consider the fact that activated immune system effector cells, such as the T-cells, are also fast dividing. Meaning that the microwaves also inhibit division of the activated immune cells thus, inhibiting the division of the activated immune cells that might have been estimated in some ways. A defeated claim for immune cell activation!!

So the microwaves Inhibit not only cancer cells replication, but also, activated immune cell replication IMO..

And IMO, the lack of interest of the medical community based on the real life experience of their patients as well as their poor quality of their remaining life at massive cost to them are all supportive of that view!!

A new & innovative alternative that stimulate the totality of the naturally occurring immune system from within is urgently needed!!

[Pedro2004]

LOL -- I tried to short this a couple of time. Got my ass kicked.

[makinezmoney]

$NVCR: You said it....... ust hit $185 in PreMarket

WOW.................. whatta MONSTER move.

$NVCR Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

GO $NVCR

[Mister Happy]

Get ready for a ride!

[HappyLibrarian]

How many shares of NVCR will be sold over the next few weeks by management?

Now that's rich!

[CrashOverride]

How many shares of NVCR will be sold over the next few weeks by management?

[jondoeuk]

Not that I'm aware of. Over the last five months or so a number of institutional buying has happened.

[rick172]

Why are the insiders selling? Is something going on?

[jondoeuk]

This thing is a pig

Calling this stock ugly doesn't make those you happen to own, such as NWBO pretty.

[jondoeuk]

AACR:

387 / 23 - Blood brain barrier (BBB) disruption by tumor treating fields (TTFields) in a human 3D in vitro model https://www.abstractsonline.com/pp8/#!/10517/presentation/12182

1305 / 15 - Tumor Treating Fields (TTFields) promote a pro-inflammatory phenotype in macrophages https://www.abstractsonline.com/pp8/#!/10517/presentation/16885

1801 / 30 - Application of Tumor Treating Fields (TTFields) to cancer cells enhances their membrane permeability https://www.abstractsonline.com/pp8/#!/10517/presentation/20545

1866 / 11 - Transcriptomics analysis for identification of pathways involved in the response to Tumor Treating Fields (TTFields) https://www.abstractsonline.com/pp8/#!/10517/presentation/16328

2037 / 15 - Spatial omic changes of malignant pleural mesothelioma following treatment using tumor-treating fields https://www.abstractsonline.com/pp8/#!/10517/presentation/12731

2601 / 14 - Concomitant treatment of ovarian cell lines with Tumor Treating Fields (TTFields) and PARP inhibitors https://www.abstractsonline.com/pp8/#!/10517/presentation/12967

2659 / 2 - Inhibition of PI3K sensitized cancer cells to Tumor Treating Fields (TTFields) https://www.abstractsonline.com/pp8/#!/10517/presentation/15079

3156 / 7 - Tumor Treating Fields reduce cellular survival of human mesenchymal stromal cells via apoptosis and senescence induction https://www.abstractsonline.com/pp8/#!/10517/presentation/14670

3252 / 21 - Tumor treating fields suppression of ciliogenesis enhances temozolomide toxicity https://www.abstractsonline.com/pp8/#!/10517/presentation/16105

3447 / 5 - Tumor treating fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord https://www.abstractsonline.com/pp8/#!/10517/presentation/12120

3450 / 8 - Impact of model inaccuracy on dose estimation in TTFields therapy https://www.abstractsonline.com/pp8/#!/10517/presentation/12124

3465 / 23 - Efficacy of concomitant application of Tumor Treating Fields (TTFields), temozolomide and lomustine in glioblastoma cancer cells in vitro https://www.abstractsonline.com/pp8/#!/10517/presentation/18151

CT234 / 5 - PANOVA-3: A phase 3 study of tumor treating fields with gemcitabine and nab-paclitaxel for front-line treatment of locally advanced pancreatic adenocarcinoma https://www.abstractsonline.com/pp8/#!/10517/presentation/20361

[jondoeuk]

The IDMC has recommended that the PhIII trial in ovarian should continue following an interim analysis. The analysis showed that an increase in sample size is not necessary and the committee recommended that the trial continue to a final analysis.

The primary endpoint of INNOVATE-3, which is examining TTFs in combination with paclitaxel for platinum-resistant ovarian, is OS. Secondary endpoints include PFS, ORR, and severity and frequency of AEs.

[TiltMyBrain]

Insiders keep dumping.

This thing is a pig

[jondoeuk]

Aren't you aware that NVCR is running five pivotal trials (brain mets from NSCLC, NSCLC, rGBM, ovarian and pancreatic) that will readout in the next few years? As for NWBO, I very much doubt we will ever see data from them, or it will be utter bull.

[exwannabe]

LOL. NWBO is toast and everybody knows it. They are morphing into a CDMO that will be worth a few hundred million.

NVCR will live or die by the lung cancer trial. If that fails they can continue to eak out an existence, but no real upside. If it works, they can say bye-bye to tiny markets like GBM.

[norisknorewards]

NWBO successful trial will crush this stock, yall heard it from me first. I see you Ex, i see you...

[exwannabe]

NVCR is going to be a trading stock for a while. I do not see any likely positive/negative drivers within the next year.

There is the IA in the ovarian trial in the next month or two. But that is so early that it is 90% to be the blah "trials continues as planned".

I doubt any real excitement on the operation/financial side. Hopefully a bit more uptick than the last set of numbers.

So, play your charts to your hearts content

[whosleftholdindabag]

Getting interesting $NVCR, how far below 200dma will it go? GLTA

[whosleftholdindabag]

Watching $NVCR closely, looking to get back in real soon! GLTA

[exwannabe]

So what exactly does the news mean?

I have never heard of a DSMB recommending that the trial stop enrollment and add a 12 month follow-up window to keep the same power.

In the proper sense, all keeping the same power means is that they expect the same number of events. If so, this could be no more that NVCR saw that enrollment was so slow they might as well just wait the 12 months than keep trying to enroll.

In the best sense, the DSMB sees the curves separating so well that they know they have sufficient patients and only need time to collect AEs.

In the worst case, the DSMB just called for a futility halt and NVCR is spinning it. In the cases where a futility halt happens before enrollment is complete. the trial can continue but it is unethical to enroll more patients. An that does match what just happened.

[crudeoil24]

Excellent news; nice upside run. More tutes increasing their position this afternoon.

[make it happen]

Agreed - Book Value Per Share $4.66

Pretty big price difference... imo

[whosleftholdindabag]

I'm donating the 1000 shares of NVCR to charity, just as I did with my NWBO shares last year. GLTA

[swampboots]

NVCR nobody here has this?
https://ih.advfn.com/stock-market/NASDAQ/novocure-NVCR/stock-news/84812177/zai-lab-partner-novocure-announces-update-on-phase

[whosleftholdindabag]

Wow, what a pre-market move! Been holding 1000 shares that I purchased after reading about NVCR over on the NWBO message board last year. Might be a good day to sell! GLTA